Symbol Lookup

Sunday September 25, 2016 1:18 PM ET. Data delayed 15 minutes.
7.33
-0.18 (-2.40%)
Bid/Lots
7.32/15
Ask/Lots
7.33/3
Open/Prev Close
7.52/7.51
Day Range
7.27-7.66
52-Week Range
4.26-20.63
Vol/Avg Daily Vol
700.2K/1.2M

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence(TM)-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain
9:15AM ET on Monday Sep 19, 2016 by PR Newswire
Companies Mentioned: CARA

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of its Phase 2b clinical trial of its oral formulation of CR845 for the treatment of pain associated with osteoarthritis. CR845, an oral tablet formulation of Cara Therapeutics' peripherally selective kappa opioid agonist, was engineered using Enteris' proprietary oral delivery technology, Peptelligence(TM).

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of its Phase 2b clinical trial ...

Sep 15, 2016

Cara Therapeutics Starts Enrollment in Phase 2b Trial For Osteoarthritis Pain Treatment
7:30AM ET on Thursday Sep 15, 2016 by MT Newswires
Companies Mentioned: CARA
07:30 AM EDT, 09/15/2016 (MT Newswires) -- Cara Therapeutics (CARA) said pre-market Thursday it started patient enrollment in a phase 2b trial that will evaluate an oral tablet formulation of CR845 as a treatment for pain associated with osteoarthri...
07:30 AM EDT, 09/15/2016 (MT Newswires) -- Cara Therapeutics (CARA) said pre-market Thursday it started patient enrollment in a phase 2b trial that will evaluate an oral tablet formulation of CR845 as a treatment for pain associated with osteoart...
BRIEF-Cara Therapeutics starts enrollment in phase 2B trial of oral CR845
7:13AM ET on Thursday Sep 15, 2016 by Thomson Reuters
Companies Mentioned: CARA

Sept 15 (Reuters) - Cara Therapeutics Inc :

* Cara Therapeutics initiates enrollment in phase 2B trial of peripherally acting kappa opioid agonist, ora...

Sept 15 (Reuters) - Cara Therapeutics Inc :

* Cara Therapeutics initiates enrollment in phase 2B trial of peripherally acting kappa opioid agonist, ora...

Cara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients
7:00AM ET on Thursday Sep 15, 2016 by GlobeNewswire
Companies Mentioned: CARA

Trial to evaluate three tablet strengths of CR845 versus placebo in approximately 330 osteoarthritis patients

Top-line data expected in first half of 2017

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of patient enrollment in a Phase 2b trial of an oral tablet formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of pain associated with osteoarthritis (OA). The Company expects to report top-line data from this trial during the first half of 2017.

Trial to evaluate three tablet strengths of CR845 versus placebo in approximately 330 osteoarthritis patients

Top-line data expected in first half of 2017

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on d...

Sep 2, 2016

Cara Therapeutics to Webcast Presentation at 23rd Annual NewsMakers in the Biotech Industry Conference
8:00AM ET on Friday Sep 02, 2016 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 23 Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016, at 10:30 a.m. ET in New York.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced t...

← Newer12Older →

Peers Headlines

Sep 22, 2016

--Analyst Actions: Maxim Begins Rating Coverage of Cellular Biomedicine Group at Buy, Sets PT at $16
8:16AM ET on Thursday Sep 22, 2016 by MT Newswires
Companies Mentioned: CBMG
08:16 AM EDT, 09/22/2016 (MT Newswires) -- Price: 14.33, Change: , Percent Change: ...

Sep 15, 2016

BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in Patients With Complete Cervical Spinal Cord Injuries
4:07PM ET on Thursday Sep 15, 2016 by Business Wire
Companies Mentioned: BTX, AST

BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its affiliate, Asterias Biotherapeutics, announced positive interim efficac...

Sep 14, 2016

Close Update: Stocks Lose Early Gains as Data Deluge Looms, Oil Retreats
4:41PM ET on Wednesday Sep 14, 2016 by MT Newswires
Companies Mentioned: F, OAS, AGN, ATW, SRPT, AST, VTAE
04:41 PM EDT, 09/14/2016 (MT Newswires) -- Stocks closed mixed on Wednesday with the Dow and S&P 500 returning early gains, but the Nasdaq Composite reversing Tuesday's loss. All three benchmark indices retreated from their session highs late in ...
Midday Update: Stocks Cautiously Higher as Tech Gains Offset Weak Energy Markets
1:02PM ET on Wednesday Sep 14, 2016 by MT Newswires
Companies Mentioned: F, OAS, AGN, XOM, AAPL, ATW, SRPT, AST, VTAE
01:02 PM EDT, 09/14/2016 (MT Newswires) -- Stocks are trading conservatively higher Wednesday with gains in the technology sector offsetting losses in the energy complex. Bargain-hunting after Tuesday's sell-off coupled with stability in the bond...
Asterias Biotherapeutics AST-OPC1 Treatment for Spinal Cord Injury Patients Shown to Help Patients Paralyzed from the Neck Down Regain Function in the Arms and Hands
10:03AM ET on Wednesday Sep 14, 2016 by PR Newswire
Companies Mentioned: AST

The News: Asterias Biotherapeutics, based in Fremont, California, announced today positive interim efficacy data in the Company's ongoing Phase 1/2a clinical study in complete cervical spinal cord injury (loss of both motor function and sensat...

Asterias Biotherapeutics Says Patients in Cervical Spinal Cord Injuries Trial Achieve Improvement
7:30AM ET on Wednesday Sep 14, 2016 by MT Newswires
Companies Mentioned: AST
07:30 AM EDT, 09/14/2016 (MT Newswires) -- Asterias Biotherapeutics (AST) said Wednesday interim efficacy data from the 10 million cell cohort in the ongoing AST-OPC1 SCiSTAR phase 1/2a multicenter clinical study in complete cervical spinal cord ...
Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with Complete Cervical Spinal Cord Injuries Treated with AST-OPC1
7:00AM ET on Wednesday Sep 14, 2016 by PR Newswire
Companies Mentioned: AST

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today presented positive interim efficacy data from the 10 million cell cohort in the Company's ongoing AST-OPC1 SCiSTAR Phase 1/2a multicenter clinical study in complete cervical spinal cord inju...

Asterias stem cell therapy shows promise in spinal cord paralysis -U.S. study
6:00AM ET on Wednesday Sep 14, 2016 by Thomson Reuters
Companies Mentioned: AST

By Bill Berkrot

NEW YORK, Sept 14 (Reuters) - An experimental stem cell therapy developed by Asterias Biotherapeutics restored some movement to patient...

Sep 13, 2016

Asterias Biotherapeutics To Disclose Interim Data In Spinal Cord Injury Trial
7:49AM ET on Tuesday Sep 13, 2016 by MT Newswires
Companies Mentioned: AST
07:49 AM EDT, 09/13/2016 (MT Newswires) -- Asterias Biotherapeutics (AST) said Dr. Charles Liu will discuss interim efficacy data from its SCiSTAR study of cervical spinal cord injury patients on a conference call Sept. 14. Liu is an investigato...
Asterias Biotherapeutics Announces AST-OPC1 SCiSTAR Study Investigator Charles Y. Liu, MD, PhD, and Director, USC Neurorestoration Center, to Discuss Interim Data on Conference Call on September 14, 2016
7:00AM ET on Tuesday Sep 13, 2016 by PR Newswire
Companies Mentioned: AST

Asterias Biotherapeutics (NYSE MKT: AST) announced today that Charles Y. Liu, MD, PhD, Director, USC Neurorestoration Center and investigator on the AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients, wi...

← Newer12Older →